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Abstract
Iodine-125 brachytherapy has been applied to brain tumours since 1979. Even though the physical and biological
characteristics make these implants particularly attractive for minimal invasive treatment, the place for stereotactic
brachytherapy is still poorly defined.
An extensive review of the literature has been performed, especially concerning indications, results and
complications. Iodine-125 seeds have been implanted in astrocytomas I-III, glioblastomas, metastases and several
other tumour entities. Outcome data given in the literature are summarized. Complications are rare in carefully
selected patients.
All in all, for highly selected patients with newly diagnosed or recurrent primary or metastatic tumours, this
method provides encouraging survival rates with relatively low complication rates and a good quality of life.
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Introduction
The implantation of radioactive material into tumours
was proposed by Pierre Curie in 1901 [1]. In 1951,
Friedlander and Orr prepared iodine-125 by alpha bom-
bardment of natural antimony [2]. In 1965, this nuclide
was finally introduced in interstitial cancer therapy
(prostate, lung cancer and lymph nodes) [3]. Mundinger
played a pioneering role in the development of the con-
cept of brachytherapy in brain tumours: he began to
implant iridium-192 wires into gliomas at 1960; since
1979 he has preferred iodine-125 seeds [4,5]. Nowadays,
temporary implantation of iodine-125 seeds is preferred
for interstitial brachytherapy in brain tumours. Despite
favourable physical and biological characteristics of bra-
chytherapy and well established implantation techniques,
so far brachytherapy treatment of brain tumours has
been performed in only a few centres worldwide. The
current review considers radiobiological characteristics,
indications, and treatment effects of iodine-125 bra-
chytherapy (including side effects) for patients with
brain tumours.
Review
Rationale for stereotactic iodine-125 brachytherapy
Interstitial brachytherapy aims for a highly localized devi-
talisation of a well defined treatment volume, thereby
avoiding damage of the surrounding non-neoplastic tissue.
Treatment volume and target volume are ideally identical.
The minimal-invasive, spatially precise stereotactic
implantation technique, in combination with favourable
physical characteristics of the radioactive sources, enable
the accurate application of highly focused necrotizing
tissue dose with a steep fall-off from the centre to the per-
iphery. The pronounced dose inhomogeneity within the
target volumes make iodine-125 brachytherapy an attrac-
tive concept, particularly for selected patients suffering
from small, circumscribed tumours at any location of the
brain. Of note, stereotactic brachytherapy must not be
confused with stereotactic radiotherapy, which exhibits
much less dose inhomogeneity and lower intratumoural
(non-necrotizing) doses, and stereotactic radiosurgery,
which is characterized by the absence of any effects of
fractionation [6-10].
Physical characteristics, dosage and dosimetry
Conventional fractionated irradiation is administered with
a dose rate of about 200cGy/min. In contrast, interstitial
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This continuous low-dose rate irradiation increases the
therapeutic ratio as the ongoing repair of sublethal irradia-
tion doses is more effective in non-neoplastic tissue, than
in tumour (see below).
Iodine-125 emits gamma-rays with a very low average
photon energy of 28.5 keV [11,12], has a specific gamma-
ray constant of 1.32-1.45R· cm
2/mCi·h [11], a long half-life
of 59.4-60.2 days [2,12-14], a half-value tissue thickness of
2 cm and for lead of 0.025 mm, which enables easy shield-
ing [4,15]. Iodine-125 implants generate a typically
extreme dose inhomogeneity within target volumes that
ranges from highly necrotizing doses surrounding the
seeds to the ultimate form of fractionation at the periphery
of target volumes [16] (Table 1).
There are two forms of iodine-125 brachytherapy tech-
niques: temporary and permanent [17] (Table 2).
Currently, temporary implants are preferred as permanent
implants bear an increased risk of prolonged oedema
[18-20]. Exclusively low activity iodine-125 seeds (<
20mCi) are preferred for slowly proliferating processes,
such as low-grade gliomas, to achieve a dose of 50-60Gy
at the tumour margin; the dose rate is usually extremely
low (10cGy/h; range 5-20cGy/h). High-dose-rate bra-
chytherapy (> 30cGy/h), as being achieved with high activ-
i t ys e e d so fu pt o4 0 m C i ,h o w e v e r ,m a yb er e q u i r e df o r
rapidly-proliferating high-grade gliomas [12,21,22].
Of note, high dose rates (30-60cGy/h) alone or in combi-
nation with external beam radiation have been shown to
be associated with a high frequency of radiogenic compli-
cations (30-50%) [23-25].
To calculate the total dose for permanent iodine-125
implants the mean life time of 87 days is used [26]. As
compared with alternative permanent implants (Au-198
and Pd-103), I-125 has been shown to be more effective
on slow growing tumours (tumour doubling time of > 10
days) [27].
Principles of seed positioning aim for a good coverage
of the target volumes with an acceptable uniformity of
the dose distribution by a minimal number of catheter
implants while sparing the surrounding anatomical struc-
tures (i.e. normal brain tissue, vessels, optic nerve etc.)
from radiation exposure [28-33]. Usually, one to five
seeds, encapsulated in the tip of a Teflon catheter, are
necessary to achieve a conformal interstitial irradiation,
even of complexly shaped tumour volumes. Of note,
iodine-125 seeds are available in various shapes, making
their dose distribution non-isotropic, which must be con-
sidered for therapy planning [11,14,34-40]. The tri-planar
treatment-planning system is based on stereotactic com-
puted tomography (CT) and magnetic resonance imaging
(MRI), as well as novel metabolic imaging data. It allows
positioning of seeds within target volumes, generate and
display the resulting isodose distribution and calculate
approach angles [32,41,42]. Care has to be taken that the
high dose zones (> 150Gy) always lie within the tumour
tissue and that vessels are not adjacent to these zones
[43].
The definition of target volumes has changed over time.
In the beginning of seed implantation in brain tumours,
the target volume was mostly determined to be the
tumour visible in CT, plus an isotropic margin of 0.5 cm
[23,30,44-47]. Presently, image fusion with magnetic reso-
nance imaging and positron emission tomography allows a
better visualisation and more precise definition of the tar-
get volume [16]. Schupak et al. found out that the techni-
cal accuracy had an impact on the local failure rate but
not on the overall survival of the patients [48].
The following parameters should be documented for
each stereotactic brachytherapy: prescribed total dose,
dose rate, minimum tumour dose, percentage of the
tumour receiving less than the prescribed dose, maximum
dose in “normal” brain at 1 cm from the tumour border,
number of seeds, activity of seeds, volumes of tumour and
surrounding tissue irradiated to various total doses and
dose rates [49].
In summary, the accurate dose distribution, the rapid
dose decrease from the centre of the treatment volume
towards the periphery, and the high doses in the tumour
and the low doses in the normal tissue, are great physi-
cal advantages of iodine-125 implants for brain tumour
therapy [16].
Biological characteristics
Theoretical models and cell culture experiments
Dale et al. have adapted the linear-quadratic (LQ)
model for protracted radiotherapy, incorporated tumour
repopulation and tumour shrinkage factors, to allow
Table 1 Isotopes used for brachytherapy in brain
tumours (Adapted from [16]).
Isotope Emission Mean energy (MeV) Half-life (days)
Iodine-125 g 0.028 60
Iridium-192 g 0.38 74
Phosphorus-32 b 0.69 14
Rhenium-186 b 0.36 4
Yttrium-90 b 0.93 3
Table 2 Parameters of permanent and temporary iodine-
125 seeds (Adapted from [13,147]).
Permanent seeds Temporary seeds
Activity per source 0.1-3mCi 3-50mCi
Dose 80-700Gy 30-200Gy
Dose rate 3-30cGy/h 3-125cGy/h
Number of sources per case 1-171 1-28
Time to dose infinity 4-50 days
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iodine-125 seeds [50-52]. Using the conventional linear-
quadratic model with an a/b = 10Gy for tumour tissue
and an a/b = 3Gy for healthy tissue and given a repo-
pulation resulting in a loss of 0.4Gy/d, 60Gy of tempor-
ary implants in 5 days are almost equivalent to 100Gy
permanent implant dose [53].
Even though the conventional LQ model describes well
the radiobiological effects of an implant at the boundary
of the target volume, it does not account for the effects
of extreme dose inhomogeneity associated with bra-
chytherapy [54]. Characteristic tissue effects associated
w i t ht h eh i g hd o s ez o n ei nt h ev i c i n i t yo ft h ei m p l a n t e d
source (≥ 200Gy) have been described experimentally,
i. e. the development of circumscribed radionecrosis with
temporary changes in capillary permeability with a some-
times extensive oedema and concomitantly reduced
regional cerebral blood flow [18-20,55,56] (see below).
The relative biological effectiveness (RBE) of iodine-125
compared to Cobalt-60 is 1.3 to 1.5 [57-59]. Compared to
iridium-192, iodine-125 has a RBE of 1 [60].
The overall low-dose-rate of iodine-125 allows reoxy-
genation for increasing radiosensitivity and cancels out the
repair of sublethal damage. Normal tissue irradiation is
essentially reduced because the exposure level decreases
by the inverse square of the distance from the source.
Therefore, the rate of tumour cell killing of brachytherapy
has been thought to be much greater than that of conven-
tionally fractionated teletherapy [22].
Animal experiments and histological studies
Iodine-125 brachytherapy reduces histological features
that are prognostic for tumour progression, i.e. cellularity,
pleomorphism, vessel hyperplasia and degree of mitosis,
and lowers the proliferating cell nuclear antigen, a marker
for late G1- and S-phases of the cell cycle [61].
To examine how the tumour microenvironment (perfu-
sion, oxygen partial pressure) changes in response to low-
dose-rate brachytherapy, experiments with a mouse
hypoxic tumour model have been performed. The perfu-
sion is elevated at a distance of 2-4 mm from the seed,
starting three days after implantation, and pO2 is increased
one to three days after implantation. Therefore, additional
external beam radiotherapy should be most advantageous
1-2 days after implantation, when pO2 is high, and che-
motherapy most advantageous 3-4 days after implantation,
when perfusion is high [62].
Autopsy material showed that the early phase after
implantation is characterized by migrating macrophages
and removal of necrotic debris. In the established phase, a
necrotic centre and a reactive zone around have been
found. The reactive zone consists of a narrow inner rim of
microglial accumulation and a broader outer area with
astrocytic gliosis, vascular proliferation, activated microglia
and infiltration by macrophages. In the burned-out phase
the necrosis undergoes liquefaction, the microglia rim is
replaced by end-stage macrophages and the reactive zone
is transformed into astrocytic gliosis equivalent to a scar
[55,63].
A radiomorphological triple ring formation has been
identified to be characteristic after seed implantation (see
below) and correlates with histopathological alterations
including a coagulative necrosis in the central radiolucent
region, a fibrinoid necrosis of vessel walls within the ring
enhancement and an adjacent spongiosis and gliosis, as
well as oedema [18]. With increasing time after implanta-
tion the ring enhancement moves outward [64].
The effect of permanent iodine-125 implants on the
blood-brain barrier (BBB) function was additionally stu-
died in normal canine brains. The breakdown of the BBB
occurs as soon as 7 days after implantation. The radiation
lesion enlarges rapidly from day 7 to 72, then increases
more slowly until day 392 and is relatively decreased in
size in 2 years. Furthermore, the finding of the three zones
with calcified necrosis, a narrow fluid-filled zone and a
narrow rim of viable but damaged tissue in which there is
breakdown of the BBB for up to 1 year before returning to
an almost normal function at 2 years, were confirmed.
Increased permeability was most pronounced in white
matter as compared to grey matter [19].
Summary of biological characteristics
Due to the continuous low-dose rate irradiation, especially
i nt h ep e r i p h e r yo ft h et a r g e tv o l u m ea n da tt h ee d g et o
normal tissue, sublethal damage can be repaired and long
term side effects of the late-responding tissue can be
avoided. In the centre of the treated volume, highly
focused necrotizing intratumoural doses with a steep dose
decrease from the centre to the periphery, such as in
radiosurgery, can be achieved. Therefore, seeds combine
the advantages of fractionated radiotherapy (repair of sur-
rounding normal tissue) and radiosurgery (tumour cell
death irrespective of radiosensitivity) in one modality.
Because repopulation and redistribution during the
treatment are of minor importance in the therapy of low
grade gliomas, low dose rate seed implantation appears to
be a rational therapeutic strategy [16].
Stereotactic biopsy and implantation techniques
Obtaining tissue diagnosis and molecular genetic profil-
ing are mandatory for each suspected brain tumour. This
can be routinely performed by means of stereotactic
biopsy procedures that integrate CT, MRI and metabolic
imaging data for trajectory planning and enable minimal-
invasive collection of representative specimens through-
out entire tumour volumes (including biologically “hot
spots” if present), especially fort h o s et u m o u r st h a ta r e
not eligible for gross open tumour resections [16,65,66].
Therefore, the authors promote a stage concept of inter-
stitial brachytherapy after versatile tissue diagnosis and
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been obtained.
Seed implantation procedure is a multidisciplinary treat-
ment involving neurosurgeons, radiation oncologists,
neuro-radiologists and physicists [16]. A detailed descrip-
tion of the stereotactic implantation technique has been
given in several reports by Kreth et al. [16,67,68]. Seed
implantation is usually performed under general anaesthe-
sia. After attaching a stereotactic ring to the patient’sh e a d ,
CT scans with a localizing system mounted on the base
ring are obtained. Then the computer based treatment
planning process starts, including 3D image reconstruc-
tion, image fusion with magnetic resonance imaging and/
or positron emission tomography, finding the optimum
seed localisations and trajectories based on the coordinate
system of the frame. The implantation of the iodine-125
seeds (length: 4.5 mm) loaded Teflon catheters is per-
formed via a 2 mm burr-hole for each catheter. CT-scan
follow-up is performed one day after surgery and fused
with the pre-operative localized CT to control the seed
positions. A hospital stay of about three days is required
for the implantation procedure. The level of radiation
upon discharge is checked and documented by the physi-
cist [12,13,16,17,30,69-74] (Figure 1). Steroids should be
administered routinely on the day of implantation and for
three days postoperatively at a daily decreasing dose of 24,
12, 8 and 4 mg dexamethasone, respectively. For tempor-
ary implants, the skin is re-opened for seed-removal after
20-30 days under local anaesthesia (no stereotactical
equipment needed).
Indications for iodine-125 brachytherapy
Iodine-125 brachytherapy is a valuable treatment option
for patients with non-resectable, small, and circumscribed
untreated tumours in any location of the brain, as well as
local circumscribed recurrences after previously performed
percutaneous radiotherapy and/or surgery [75]. Ideally, the
diameter of the tumour should be smaller than 3 cm. In
case of larger tumour volumes, microsurgery (partial
resection) might be combined with brachytherapy [17]. Of
note, interstitial brachytherapy can be performed even in
cases in which tolerance of the healthy brain tissue has
been reached because of previous external irradiation and/
or stereotactic radiosurgery [4,76]. Implantation is also a
valuable technique in certain paediatric patients [77,78].
For a long time, infratentorial masses, the hypothalamic
region, the middle-inferior mesencephalon, the diencepha-
lon, the pons, the corpus callosum and tumours with sub-
ependymal or transcallosal spread, involvement of the
cerebellum, the brainstem or t h ed e e pt h a l a m i cr e g i o n s ,
involvement of basal ganglia structures, sylvian or interhe-
mispheric fissures, have been considered contraindicated
sites for implantation. Furthermore, large tumours > 6 cm
or with a tumour volume of > 120 ml, multifocal masses,
and those with diffuse margins, patients with a Karnofsky
performance status (KPS) of < 60 and significant oedema,
have been thought to be not suitable for implantation
[12,13,46,73,79-82]. Currently, technical indications have
been extended [83,84]. Only diffuse tumours, tumours
with a diameter larger than 4 cm, or with infiltration of
the corpus callosum, are still considered to be insuitable
for implantation [16].
Follow-up characteristics
During MRI follow-up evaluation, a characteristic triple
ring formation can be identified, which should not be con-
fused with tumour progression [64]. The inner zone of
this formation refers to the necrotized tumour, the inter-
mediate contrast enhanced zone to a small rim of a still
viable tumour, exhibiting increased capillary permeability,
and the outer zone to the treatment induced oedema. The
ring shaped area of contrast-enhancement is visible 4.5
months to 3 years after implantation [85]. A study on
volumetric changes in tumour necrosis, reactive zone and
oedema over the time after temporary seed implantation
Figure 1 Sequence of steps in using the BRW stereotactic
system [21]. A: The head ring is fixed to the skull. B: The localizing
ring with its nine carbon-fibre rods is attached to the head ring for
CT scanning. C: A sample CT cut shows the circular cross sections of
the localizing rods. D: The pin and arc device are attached to the
phantom base plate to check the computed settings for the desired
trocar placement. E: The pin and arc device are attached to the
head ring on the patient.
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reference dose volume the necrosis has been 19.9% after 6
months, 8.3% after 14 months and 7.0% after 24 months,
the reactive zone 30.4%, 34.8% and 16.7%, respectively,
and the oedema 293.2%, 220.5% and 107.0%, respectively.
Necrosis has been found in regions with > 79.2Gy with a
maximum 6 months after irradiation, a shrinkage between
9 and 15 months and a steady-state after 16 months. The
reactive zone has had its maximum 2 months after irradia-
tion, after 12 months the shrinkage has been more pro-
nounced. The maximum of the oedema has been reached
after 6 months [86].
Other visible late radiation effects (> 2 months) are
decreased enhancement of the tumour region, decreased
mass effect, atrophic changes in surrounding brain
(widened sulci), calcification in areas immediately adjacent
to the seeds, and focal necrosis corresponding to the treat-
ment volume, surrounded by a zone of decreased cerebral
metabolism in positron emission tomography (PET) [47].
To monitor iodine-125 brachytherapy effects in low-
grade gliomas with PET L-methyl-carbon-11-methionine
uptake seems to be more suitable than 2-fluoro-18-1-
deoxy-D-glucose (FDG), as it shows a dose dependent
decline in uptake [87,88].
A magnetic resonance imaging study compared longi-
tudinally features of patients either treated with external
beam radiotherapy alone or in combination with bra-
chytherapy. In both groups, nodular enhancement adja-
cent to or remote from the resection cavity strongly
suggests tumour recurrence. Linear rim enhancement,
later on progressing to feathery enhancement, immediately
adjacent to the cavity, has been seen in brachytherapy
patients only and strongly indicates radiation necrosis [89].
Clinical indications and results
The results concerning survival achieved with permanent
and temporary brachytherapy implants in patients with
various brain tumours are summarized in Table 3. For
recurrent tumours, survival is measured starting from
time of implantation. In the following section indications,
clinical outcome, risk limits and side effects are given for
different brain tumour entities.
Brachytherapy of pilocytic astrocytomas WHO grade I
Pilocytic astrocytomas frequently involve paediatric
patients. Open tumour resection remains to be the gold
standard, with favourable survival rates, provided complete
tumour removal has been achieved. Unfortunately, these
tumours are often found in highly eloquent locations such
as the chiasmatic/hypothalamic area, the thalamus, the
tractus opticus etc., rendering a complete resection impos-
sible for a considerable number of patients. Poor physical,
cognitive, and psychosocial outcome scores have been
reported after long-term follow-up evaluation in particular
for those patients with deep-seated tumour locations
(diencephalon, optic chiasm, etc.). In here, an unfavour-
able outcome was at least partly attributed to side effects
of surgical treatment [90-92].
In 1980, Mundinger et al. reported the first survival
results of 55 young patients with diencephalic pilocytic
astrocytomas treated with iodine-125 or iridium-192 inter-
stitial brachytherapy. In this patient population 3- and 5-
year survival rates of 72% and 52% have been achieved [4].
In paediatric patients the 1-, 3- and 5-year survival rates
were slightly better for permanent iridium-192 (88%, 70%
and 55%) than for iodine-125 implants (86%, 58% and
22%). Both nuclides proved to be more effective than
biopsy or partial resection only [93]. Others report a
2-year survival rate of 83% for paediatric patients and tem-
porary iodine-125 implants [94].
Another retrospective analysis revealed 1- and 3-year
survival rates of 94% and 73% for newly diagnosed (trea-
ted in combination with percutaneous radiotherapy) and
of 68% and 30% for recurrent (treated with brachytherapy
alone) low grade gliomas [25].
The largest series with 106 pilocytic astrocytoma
patients was published by Ostertag and Kreth. Patients
were either treated with permanent or temporary
implants; a 5-year survival rate of 77% was obtained and
radiation toxicity was mostly observed in patients treated
with permanent implants [95]. 5- and 10-year survival
rates of up to 85% and 83% have been reported by
another publication [68].
Of note, treatment of a subpopulation of 45 highly elo-
quent hypothalamic tumours was associated with low risk
and provided similar clinical outcome rates. Peraud and
co-workers report on clinical outcome after temporary
iodine-125 implantation (54Gy, 8cGy/h, < 20mCi) for
complex located WHO grade I and II gliomas (including 4
mesencephalic/pontine, 2 thalamic/pineal and 2 mesence-
phalic/pontine tumour locations) [72]. A complete
response after brachytherap yw a ss e e ni nf o u rp a t i e n t s ,
and a partial response in seven patients. None of the
patients exhibited tumour progression within a median
follow-up of 31.5 months, and no radiogenic complica-
tions occurred. Of note, functional outcome scores were
favourable with significant improvement of pre-existing
hemiparesis in 3/4 patients, improvement of endocrine
deficits in one half of patients, and improvement of visual
functioning in 1/3 patients. Other retrospective data are in
line with these findings [94]. Of note, long term side
effects of brachytherapy seem to be rare in the paediatric
subpopulation [96].
To summarize, studies on brachytherapy in pilocytic
astrocytomas WHO grade I are rare and retrospective.
Therefore, no clear conclusion can be drawn concerning
indications for brachytherapy for these tumours. How-
ever, stereotactic iodine-125 brachytherapy has been
s h o w nt ob eas a f e ,m i n i m a l l yi n v a s i v e ,a n da ne f f e c t i v e
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Study Number
of
patients
&
type of
iodine-
125 seeds
Dose, dose
rate, activity
Diagnoses (number
of patients) &
additional
percutaneous
radiotherapy (pRT)
6
months-
survival
rate
9
months-
survival
rate
12
months-
survival
rate
18
months-
survival
rate
2 year-
survival
rate
3 year-
survival
rate
4 year-
survival
rate
5 year-
survival
rate
8 year-
survival
rate
10 year-
survival
rate
15 year-
survival
rate
Median
survival
Mundinger
1980 [4]
221
iodine-125
& iridium-
192
Astrocytomas I (55) 72% 52%
Astrocytomas II (76) 69% 44%
Astrocytomas III (34) 66% 47%
Oligodendrogliomas II/
III (26)
65% 27%
Glioblastomas (17)
Germinomas (13) 19% 30%
Leibel
1984 [194]
43
temporary
80-120Gy Recurrent primary
tumours
preirradiated
>1 8
months
Wara
1985 [189]
temporary Recurrent malignant
gliomas
18
months
Leibel
1985 [195]
43
temporary
80-120Gy Recurrent primary
tumours
preirradiated
18
months
Leibel
1986 [111]
77
temporary
50-120Gy Recurrent tumours:
Astrocytomas III (42) 49% 22
months
Glioblastomas (35)
all preirradiated
26% 17
months
Gutin
1987 [110]
41
temporary
57.4-120Gy Recurrent tumours:
25-100cGy/h Astrocytomas III (23) 35
months
30-40mCi Glioblastomas (18)
preirradiated (44-
70.5Gy)
8
months
Wright
1987 [47]
14
temporary
100-280Gy New tumours (12) 2-32
months
2
permanent
15-30cGy/h
6-144mCi
Additional pRT (45Gy)
Recurrent tumours (4)
Preirradiated
Glioblastomas (12)
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Willis
1988 [46]
17
temporary
New: New glioblastomas (5) 100% 75% 25%
60Gy Additional pRT
(50.4Gy)
35-64cGy/h
34-239mCi
Recurrent: Recurrent tumours (12) 93% 60% 50% 38%
80Gy Astrocytomas III (8)
30-65cGy/h
122-320mCi
Glioblastomas (4)
preirradiated (50.4-
66Gy)
Leibel
1988 [44]
95
temporary
50-120Gy
Recurrent tumours: 55% 40% 20
months
Astrocytomas III (50) 30% 15% 12
months
Glioblastomas (45)
preirradiated
Prados
1989 [158]
14
temporary
50cGy/h
10-40mCi
Metastases
preirradiated
18
months
Etou
1989 [93]
56
temporary
&
permanent
90-100Gy Paediatric tumours:
Astrocytomas I (36) 86% 58% 22%
Astrocytomas II (14) 79% 36% 21%
Astrocytomas III (6) 33% 17% 17%
Malkin
1989 [127]
21
temporary
60Gy Astrocytomas III (2)
36cGy/h Glioblastomas (19) 6
months
79-495mCi Recurrent tumours
(10):
Preirradiated
Yakar
1989 [159]
50
temporary
55-60Gy New tumours: 11
months
(mean)
40cGy/h Astrocytomas III (3)
4-299mCi Glioblastomas (17)
Additional pRT (50-
60Gy)
Recurrent tumours: 13
months
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Astrocytomas III (5)
Glioblastomas (12)
Preirradiated
Metastases (13) 8
months
(mean)
Leibel
1989 [45]
95
temporary
52.7-150Gy Recurrent tumours:
20-90cGy/h Astrocytomas III (50) 46% 28% 19
months
27-372mCi Glioblastomas (45)
preirradiated (40-72Gy)
22% 8% 12
months
Larson
1990 [81]
128
temporary
46-120Gy New tumours:
25-100cGy/h Astrocytomas III (20) 51
months
Glioblastomas (13) 22
months
Additional pRT (60Gy)
Recurrent tumours:
Astrocytomas III (50) 45% 28% 19
months
Glioblastomas (45)
Preirradiated
22% 8% 12
months
Bernstein
1990 [107]
46
temporary
New: New tumours:
60Gy Astrocytomas III (23) 14
months
Additional pRT (50Gy)
Recurrent: Recurrent tumours:
70Gy Astrocytomas III (18) 10
months
21.8-125cGy/
h 93-599mCi
Metastases (3)
Radiation-induced
tumours (2)
preirradiated
Loeffler
1990 [134]
35
temporary
38-55Gy Glioblastomas (35) 87% 57%
30-60cGy/h
20-50mCi
Additional pRT
(59.4Gy)
Gutin
1990 [109]
55
temporary
50Gy Astrocytomas III (25) 36
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Glioblastomas (30)
Additional pRT (60Gy)
20
months
Gutin
1991 [23]
63
temporary
50-60Gy Astrocytomas III (29) 36
months
40-60cGy/h
10-40mCi
Glioblastomas (34)
Additional pRT (60Gy)
20
months
Clark
1991 [108]
25
temporary
60Gy Astrocytomas III (4) 30
months
Glioblastomas (21)
Additional pRT
21
months
Loeffler
1991 [135]
25
temporary
39-64Gy Recurrent
Glioblastomas (25)
42% 30% 15% 10
months
Scharfen
1991 [113]
334
temporary
37-150Gy New tumours:
25-100cGy/h Astrocytomas III (80) 74%
Glioblastomas (117) 33%
Additional pRT
Recurrent tumours:
Astrocytomas III (70) 41%
Glioblastomas (67) 23%
Zamorano
1992 [160]
64
temporary
Temporary: New tumours: 75% 47% 15
months
50
permanent
60Gy Astrocytomas III
40cGy/h Glioblastomas
Additional pRT (50Gy)
Permanent: pRT®temporary (25) 59% 30% 14
months
81-143Gy permanent®pRT (19) 79% 59%
4-7cGy/h pRT®permanent (9) 100% 50% 13
months
permanent only (9) 100%
Recurrent tumours: 38% 13% 10
months
temporary (23) 39% 10% 10
months
permanent (11) 36% 36% 9
months
Metastases:
temporary (16) 44% 28% 10
months
permanent (2) 44% 25% 10
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Zamorano
1992 [161]
50
temporary
55-60Gy New tumours: 11
months
(mean)
40cGy/h Astrocytomas III (3)
4-299mCi Glioblastomas (17)
Additional pRT (50-
60Gy)
13
months
Recurrent tumours:
Astrocytomas III (5)
Glioblastomas (12)
Preirradiated
Metastases (13) 8
months
(mean)
Sneed
1992 [145]
206
temporary
New: New tumours:
42-76Gy Astrocytomas III (29) 36
months
Glioblastomas (34) 20
months
Additional pRT (60Gy)
Recurrent: Recurrent tumours:
53-150Gy Astrocytomas III (50) 19
months
20-90cGy/h Glioblastomas (45) 12
months
Preirradiated
Hyperthermia: Recurrent tumours:
33-63Gy Astrocytomas III (16) 81% 65%
Glioblastomas (25) 45% 11
months
Metastases (7)
Plus hyperthermia
10
months
Yakar
1992 [115]
62
temporary
Temporary: New tumours: 40% 14
months
60Gy Astrocytomas III (7) 43% 13
months
40cGy/h Glioblastomas (18) 39% 15
months
Additional pRT
Recurrent tumours: 23% 11
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Astrocytomas III (8) 37% 9
months
Glioblastomas (13) 8% 11
months
Metastases (16) 25% 10
months
55
permanent
Permanent: New tumours: 73% 37
months
100Gy Astrocytomas III (36) 79% 37
months
5cGy/h Glioblastomas (5) 27% 14
months
Recurrent tumours: 42% 14
months
Astrocytomas III (7) 86% 23
months
Glioblastomas (4) 0% 6
months
Metastases (3) 33% 4
months
Scharfen
1992 [25]
307
temporary
37-120Gy New tumours:
19-140cGy/h Non-glioblastomas
(68):
38-453mCi Astrocytomas I/II 94% 73% 52
months
Astrocytomas III 85% 47% 33
months
Glioblastomas (106) 86% 22% 20
months
Additional pRT (60Gy)
Recurrent tumours:
Non-glioblastomas
(67):
Astrocytomas I/II 68% 30% 19
months
Astrocytomas III 49% 24% 12
months
Glioblastomas (66) 50% 15% 11
months
Prados
1992 [112]
88
temporary
50-60Gy Astrocytomas III (32) 32% 37
months
40-60cGy/h
10-40mCi
Glioblastomas (56)
Additional pRT (40-
77Gy)
29% 14% 20
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Ostertag
1992 [95]
194
temporary
345
permanent
30-70Gy Astrocytomas I (106) 77%
10cGy/h Astrocytomas II (251) 65% 64%
Oligoastrocytomas (44) 80%
Oligodendrogliomas
(29)
58%
Astrocytomas III (75) 49% 36% 8
months
Glioblastomas (34) 48% 16% 6
months
Kreth
1993 [162]
81
temporary
60Gy New metastases:
10cGy/h WBRT (40Gy) + seed
(38)
17
months
Seed only (22) 12
months
WBRT (40Gy) only (49) 8
months
Recurrent metastases:
seed only (21)
preirradiated
6
months
Fontanesi
1993 [118]
26
temporary
60Gy Astrocytomas III (9) 20
months
40-45cGy/h
7-25mCi
Glioblastomas (17)
Additional pRT
(66Gy@2x1.1Gy/d)
13
months
Voges
1993 [82]
1
temporary
40Gy Ependymomas (1) 100%
3cGy/h
21.4mCi
Kreth
1993 [104]
134
temporary
50-60Gy Astrocytomas II (251) 64%
190
permanent
10cGy/h Oligoastrocytomas II
(44)
80%
Oligodendrogliomas II
(29)
58%
Sneed
1994 [136]
34
temporary
42-66Gy Glioblastomas (34) 91% 40% 18% 9% 21
months
30-60cGy/h Additional pRT (56-
60Gy)
Wen
1994 [137]
56
temporary
50Gy Glioblastomas (56) 83% 34% 27% 16% 18
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
30-60cGy/h
20-50mCi
Additional pRT (59.4Gy
@1.8Gy/d or
40Gy@2x2Gy/d)
Bernstein
1994 [79]
46
temporary
70Gy Recurrent tumours: 11
months
68cGy/h Astrocytomas II (2)
293mCi Astrocytomas III (12)
Glioblastomas (32)
preirradiated (50-60Gy)
Ryken
1994 [126]
15
temporary
60Gy or 80-
300Gy
Recurrent tumours: 6
months
5
permanent
40cGy/h Astrocytomas III (9)
Glioblastomas (11)
Preirradiated (60Gy)
Hitchon
1994 [125]
26 Astrocytomas III or
Glioblastomas (26)
18
months
Fernandez
1994 [116]
73
permanent
100-120Gy Astrocytomas III or
Glioblastomas (73)
82% >3 1
months
4-7cGy/h Additional pRT (50-
60Gy)
(16% before, 68%
concurrent, 15% not)
>2 3
months
Kitchen
1994 [144]
23
temporary
50Gy Recurrent
astrocytomas III or
glioblastomas (23)
6
months
40-230mCi Preirradiated (50-60Gy)
Gaspar
1994 [119]
72
permanent
100Gy Astrocytomas III (45) 80% 70% 62%
5cGy/h Glioblastomas (27)
Additional pRT (50-
60Gy)
(62% before, 24% after,
14% not)
80% 55% 40%
Scerrati
1994 [105]
32 iridium-
192
43Gy or 90Gy Astrocytomas I (2) 83% 57% 39% 112
months
4 iodine-
125
14
temporary
22
permanent
32cGy/h or
42cGy/h
Astrocytomas II (23)
Oligodendrogliomas
(11)
Additional pRT (30-
54Gy)
Zamorano
1995 [123]
72
permanent
5cGy/h Astrocytomas III (45) 84% 75% 65%
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Glioblastomas (27)
Additional pRT (50-
60Gy)
(24% before, 63% after,
14% not)
80% 53% 26
months
Chamberlain
1995 [185]
45-51Gy Recurrent tumours:
16
temporary
50cGy/h Astrocytomas III (3) 9
months
Oligodendrogliomas III
(1)
Glioblastomas (11)
Ependymomas (1)
Preirradiated (54-60Gy)
Kreth
1995 [68]
194
temporary
261
permanent
60-100Gy Astrocytomas I (97) 85% 83%
< 10cGy/h Astrocytomas II (250) 61% 51%
Oligoastrocytomas (60) 49% 58
months
Oligodendrogliomas
(27)
50% 61
months
Gemistocytic gliomas
(21)
32% 37
months
Fernandez
1995 [117]
58
permanent
102Gy Astrocytomas III (40) >3 1
months
4-7cGy/h Glioblastomas (18) >2 3
months
0.1-32mCi Additional pRT (50-
60Gy)
(17% before, 66% after,
17% not)
Sneed
1995 [141]
159
temporary
36-67Gy Glioblastomas (159) 85% 36% 20% 19
months
30-70cGy/h Additional pRT (40-
77Gy)
Ostertag
1995 [150]
93
temporary
60-100Gy
10cGy/h
New metastases:
Seed + pRT (40Gy)
(38)
17
months
seed only (34) 15
months
Recurrent Metastases:
Preirradiated (21)
6
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Halligan
1996 [128]
22
permanent
150-300Gy Recurrent tumours: 57% 15
months
11cGy/h Astrocytomas III (4)
39mCi Glioblastomas (18)
Preirradiated (54-65Gy)
59% 15
months
Kreth
1997 [99]
197
temporary
&
permanent
45-100Gy or Astrocytomas II (153) 60%
50-120Gy Oligoastrocytomas II
(44)
3-18cGy/h Additional pRT (47) 17
months
Sneed
1997 [12]
permanent 60-100Gy Astrocytomas I 85% 83%
5-10cGy/h Astrocytomas II 61% 51%
Sneed
1997 [12]
temporary 60Gy New high-grade
gliomas
18-19
months
40-60cGy/h Recurrent high-grade
gliomas
12-13
months
Schulder
1997 [151]
13
permanent
43-132Gy Metastases (13) 8
months
0.26-0.79mCi Additional pRT (30-
75Gy)
Chamberlain
1997 [138]
15
temporary
50Gy
50cGy/h
Recurrent
glioblastomas (15)
10
months
Laperriere
1998 [24]
63
temporary
57-68Gy Malignant
astrocytomas (140)
21-125cGy/h Additional pRT (50Gy)
(63)
16
months
only pRT (50Gy) (69) 13
months
Gaspar
1999 [53]
59
permanent
100Gy Recurrent tumours:
5cGy/h Astrocytomas III (22) 76% 55% 32% 16
months
Glioblastomas (37) 44% 13% 24
months
preirradiated (50-66Gy) 11
months
Videtic
1999, 2001
[121,122]
75
permanent
100Gy Astrocytomas III (22) 58% 40% 40
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
5cGy/h Glioblastomas (53)
Additional pRT (50-
60Gy)
40-42% 18% 16-17
months
Suplica
1999 [142]
38
permanent
100-500Gy Recurrent
glioblastomas (38)
12
months
0.67mCi Preirradiated (59-72Gy)
Patel
2000 [140]
40
permanent
120-160Gy
0.58-0.86mCi
Recurrent
glioblastomas (40)
preirradiated (60Gy)
72% 11
months
Koot
2000 [139]
comment
[196]
33
temporary
12
permanent
50-80Gy
3-5cGy/h
5-40mCi
Glioblastomas (45)
Additional pRT (10-
30Gy)
13
months
Rostomily
2001 [197]
6
permanent
160-218Gy Recurrent paediatric
tumours:
22
months
10cGy/h
23-76mCi
Primitive
neuroectodermal
tumours (2)
Medulloblastomas (1)
Ependymomas (1)
Xanthoastrocytomas
(1)
Glioblastomas (1)
preirradiated (3
craniospinal, 2 WBRT)
Keole
2001 [132]
26
permanent
83-100Gy Glioblastomas (26)
Additional pRT (57-
61Gy)
23
months
Huang
2002 [153]
28
permanent
200-500Gy Metastases: 11
months
15-69mCi New (16) 14
months
Recurrent (12) 5
months
Zamorano
2003 [124]
60
permanent
100Gy Astrocytomas III (57) 87% 60% 50% 46% 57
months
3-7cGy/h Oligodendrogliomas III
(3)
Additional pRT (50-
60Gy)
(78% before, 22% not)
Larson
2004 [133]
35
permanent
150-500Gy
7-24cGy/h
56mCi
Recurrent
glioblastomas (35)
Preirradiated (59-72Gy)
12
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Mehrkens
2004 [101]
55
temporary
&
permanent
60-100Gy
3-10cGy/h
Astrocytomas II (46)
Oligoastrocytomas II
(9)
55% 28% 68
months
Kreth
2006 [67]
136
temporary
100Gy Astrocytomas II (187) 56% 37% 26%
103
permanent
60Gy
8cGy/h
Oligoastrocytomas II
(52)
Herrera
2007 [94]
12
temporary
52-80Gy Paediatric
astrocytomas I (12)
83%
4-20cGy/h
11-41mCi
Julow
2007 [98]
43
temporary
40-200Gy Astrocytomas I/II (27) 93% 61% 40% 36
months
1-83cGy/h Astrocytomas III (10) 48% 19% 0% 16
months
12-155mCi Glioblastomas (6) 17% 0% 0% 8
months
New tumours (11)
Recurrent tumours (32)
Dagnew
2007 [155]
26
permanent
120-200Gy Metastases (26) 72% 46% 18
months
Chen
2007 [130]
18
permanent
200-600Gy Glioblastomas (18) 26
months
21-95mCi Additional pRT (60Gy@
2x1Gy/d)
Schnell
2008 [102]
31
temporary
54Gy New astrocytomas II
(18)
93%
10cGy/h Recurrent
astrocytomas II (13)
Darakchiev
2008 [131]
34
permanent
120Gy
27mCi
Recurrent
glioblastomas (34)
82% 66% 37% 23% 16
months
Huang
2009 [156]
40
permanent
200-700Gy New metastases (19) 47% 21% 12
months
10-69mCi Recurrent metastases
(21)
33% 14% 7
months
Petr
2009 [157]
72
permanent
150Gy
4-40mCi
Metastases (72) 55% 27% 14
months
Schwarz
2009 [120]
71
temporary
20-60Gy Astrocytomas I (4)
10-82mCi Astrocytomas II (30) 41
months
Astrocytomas III (11) 12
months
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8Table 3 Results concerning survival achieved with permanent and temporary iodine-125 brachytherapy in patients with various brain tumours. (Continued)
Glioblastomas (13) 4
months
Medulloblastomas (4)
Oligodendrogliomas
(3)
Pinealis tumour (1)
Metastases (5)
Preirradiated (18-80Gy) 22
months
Ruge 2011
[149]
77
temporary
50Gy
6cGy/h
Metastases (77) 8
months
Korinthenberg
2011 [198]
94
temporary
60Gy Paediatric tumours: 97% 92%
10cGy/h Astrocytomas I (53)
10mCi Astrocytomas II (26)
Oligoastrocytomas II
(4)
Oligodendrogliomas II
(5)
Ependymoma II (1)
Not classified (5)
El Majdoub
2011 [183]
11
temporary
32-50Gy Recurrent
Medulloblastomas (12)
67% 33% 18
months
1
permanent
2-40mCi Preirradiated (24-56Gy)
Ruge 2011
[154]
90
temporary
50Gy
3-6cGy/h
Metastases (90) 9
months
Suchorska
2011 [106]
95
temporary
50-65Gy Astrocytomas II (69) 238
months
3cGy/h Oligoastrocytomas II
(14)
12mCi Oligodendrogliomas II
(12)
Ruge 2011
[199]
147
temporary
65Gy Children:
1-31mCi Astrocytomas I (101) 100% 98% 93% 82%
Astrocytomas II (34) 96% 85%
Other (12) 85% 77%
Ruge 2011
[163]
50Gy Metastases 15
months
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8first-line treatment option for selected patients with
highly eloquent tumour locations, bearing a high risk for
open tumour resection. As pilocytic astrocytomas are
mostly slow growing, sharply marginated tumours in the
midline and highly eloquent areas, brachytherapy should
be considered an attractive option.
Brachytherapy of gliomas WHO grade II-IV
Many more patients with gliomas WHO grade II-IV have
been treated with iodine-125 implants. However, the place
of interstitial brachytherapy remains poorly defined. More-
over, the effects of an oligodendroglial differentiation, as
well as recently discovered molecular genetic markers
(such as LOH1p/19q, TP53 mutations, MGMT promoter
methylation and IDH1 mutations), on the efficiency of
interstitial brachytherapy, have not been evaluated yet [16].
Brachytherapy of gliomas WHO grade II
Results of brachytherapy for low grade gliomas WHO
grade II - as first line treatment option - have been already
summarized before [97]. Most data come from retrospec-
tive studies: 1-, 3- and 5-year survival rates in the range of
79-94%, 36-73% and 21-65% for primary tumours and 1-
and 3-year survival rates of around 68% and 30% for recur-
rent tumours have been reported [4,12,25,67,68,93,
95,98-101].
The response rates of astrocytomas WHO grade II for
iodine-125 brachytherapy included 7.5-25.8% complete
responses, 13.8-29.0% partial responses, and 45.2-61.1%
stable diseases. The rate of non-responders ranges
between 0% and 17.6% [67,102].
One of the largest long-term analysis (median follow-up:
10.3 years) reports on interstitial brachytherapy in 239
patients with progressive eloquently located circum-
scribed, supratentorial WHO grade II gliomas [67]. In 103
patients permanent implants were used, since 1985 tem-
porary implants have been preferred. Five-, 10-, and 15-
year progression free survival was 45%, 21%, and 14%,
respectively. The corresponding survival rates were 51%,
32%, and 22%, respectively. Of note, no levelling off of
the Kaplan Meier curves was observed and patients experi-
enced tumour progression even 10 years after treatment.
Complete response was seen in 18 patients, partial
response in 33 patients, tumour control in 146 patients,
and unrestrained tumour progression in 42 patients (non-
responder group). Transient radiogenic complications
occurred in 19 patients.
Schnell et al. found a 5-year survival rate as high as
93% in patients with low activity temporary iodine-125
implants (54Gy, 10cGy/h) [102].
Malignant transformation of astrocytomas II was seen in
33% of the patients after 5 years, in 54% after 10 years and
in 67% after 15 years [67], but was not different to open
tumour resection alone [16].
In a retrospective analysis, Warnke and co-workers
observed a significant reduction of seizure incidence and
increase of benzodiazepine receptor density (as demon-
strated by single photon emission computed tomogra-
phy in a subset of 20 patients), after brachytherapy of
80 patients with temporal WHO grade II astrocytomas
[103]. Of note, 79% of patients became seizure free after
six months.
For astrocytomas grade II, a significantly better outcome
with less radiation toxicity was reached with temporary
seeds than with permanent ones, which are associated with
an increased risk for prolonged oedema [95,100,101,104].
Target volume and radiation dose showed a direct correla-
tion with the risk of radionecrosis with critical values being
35 cm
3 and 100Gy for permanent and 50Gy at 42cGy/h
for temporary implants [105]. Age, KPS, midline shift,
tumour volume and enhancement on CT were predictors
for outcome [68,95,99-101].
A combination of microsurgery and stereotactic bra-
chytherapy for tumour remnants is feasible and might be
an alternative treatment strategy, for example, for large
lesions with significant proportions of eloquent tumour
parts to avoid neurological deficits [16]. Brachytherapy to
treat progressive or recurrent tumours after resection
achieved a tumour response rate of 35.9% and a control
rate of 97.3% after 24 months; median progression free
survival was 53 months [106].
All in all, even though stereotactic brachytherapy has
been used for low-grade gliomas for many years, its place
within the multimodality treatment concept is still
debated [16]. Small (less than 4 cm in diameter), circum-
scribed lesions in highly eloquent or deep-seated tumour
locations might be good candidates for interstitial bra-
chytherapy, especially in cases harbouring an increased
risk for open tumour resection. Moreover, radiobiology,
tumour shape and the option of percutaneous radiother-
apy for recurrence, favour an increased application of
brachytherapy in astrocytomas grade II.
Brachytherapy of anaplastic gliomas WHO grade III
For newly diagnosed anaplastic astrocytomas WHO
grade III, standard therapy consists of radiation therapy
with/-out surgical resection, whenever safely possible.
Alternatively, first line chemotherapy might be consid-
ered (NOA-04 study). However, interstitial brachytherapy
might also be a local treatment option, especially for
those patients that are not clear surgical cases.
For newly diagnosed anaplastic astrocytomas, the com-
bination of interstitial brachytherapy with percutaneous
radiotherapy has been shown to be associated with 1-, 2-,
3- and 5-year survival rates of 33-87%, 36-75%, 17-66%
and 0-50%. Median survival is also highly variable and
ranges between 8-57 months. Patients treated with seeds
for recurrent anaplastic astrocytomas had 1-, 2- and 3-
year survival rates of 49-81%, 46-55% and 24-40% and a
median survival of 9-35 months after implantation
[4,23,25,44,45,53,81,93,95,98,107-124].
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patients treated with percutaneous radiotherapy in com-
bination with temporary iodine-125 implants, compared
to external irradiation alone [24,125]. While in the
NCOG 6G-82-2 study, the brachytherapy boost had no
additional advantage [23].
Gutin et al. compared survival after iodine-125 bra-
chytherapy for recurrent anaplastic astrocytomas to that
of a historical chemotherapy group and obtained better
survival data for the brachytherapy group [110].
Factors associated with improved survival were age ≤
45-50 years, KPS ≥ 80-90, superficial location, decreas-
ing volume of implanted tumour, chemotherapy at
recurrence and reoperation at the original site in case of
tumour recurrence [24,117,124,126].
Different schemes have been used for primary therapy.
On the one hand, 50-60Gy of temporary implants have
been combined with 50-60Gy percutaneous radiotherapy
[24,81,107]. On the other hand, 100Gy of permanent
implants have been added to 50-60Gy external beam
radiotherapy [124]. Sometimes seeds had been
implanted before percutaneous radiotherapy had been
started [108].
There was as well a lot of variation in therapy for
recurrent, pre-irradiated astrocytomas III. Doses of 50-
150Gy have been employed with temporary implants
[44,45,107,111,127]; 100-300Gy with permanent [53,128].
To summarize, multiple, even several randomized, stu-
dies were performed to analyze the value of brachyther-
a p yi nt h ep r i m a r yt r e a t m e n tof astrocytomas grade III,
but failed to prove any clear beneficial efficacy for this
tumour entity. Therefore, standard therapy is radiother-
apy or chemotherapy according to the results of the
NOA-04 study [129]. However, for recurrent, pre-irra-
diated tumours, seeds might be a valuable option.
Brachytherapy of glioblastomas WHO grade IV
Interstitial brachytherapy has been repeatedly suggested
for malignant gliomas WHO grade IV at primary diagno-
sis, as well as during the course of the disease. For primary
glioblastomas, 1-, 2-, 3- and 5-year survival rates of 80-
91%, 19-57%, 14-40% and 9-18% and a median survival of
13-26 months could be achieved. 1-, 2- and 3-year survival
rates for recurrent tumours were 44-66%, 13-26% and 8-
15%, and median survival 6-17 months [4,23,25,44,45,53,
81,95,108-119,121-123,128,130-142].
Several retrospective studies showed a better survival
for patients with primary glioblastomas treated with a
temporary or permanent brachytherapy boost, in addition
to parallel or sequential external beam irradiation,
instead of percutaneous radiotherapy alone (e.g. 1-, 2-, 3-
and 4-year survival rates have been 40%, 12.5%, 9% and
5% compared to 83-87%, 34-57%, 27% and 16%; median
survival 11 months vs. 18 months) [134,137]. There was
no survival difference for iridium-192 and iodine-125
[139], or brachytherapy and radiosurgery boost [132], but
permanent implants showed improved survival compared
to temporary [115].
Percutaneous and interstitial irradiation in newly diag-
nosed paediatric malignant gliomas have been comple-
mented by high-dose chemotherapy and autologous
bone marrow rescue, but was not associated with better
outcome scores than for conventional regimens [143].
For recurrent glioblastomas, tumour resection plus
permanent seed implantation was compared to biopsy
plus temporary seed implantation, and revealed similar
median survival rates [133].
Subgroup analyses of the results for primary treatment
of anaplastic astrocytomas and glioblastomas with percu-
taneous radiotherapy and permanent brachytherapy
boost, divided into the RTOG recursive partitioning ana-
lysis (RPA) classes, have shown the following results: the
2-year survival rate and the median survival for RPA
classes I/II were 68% and 37 months, for class III 74%
and 28-31 months, for class IV 32-34% and 16 months
and for classes V/VI 29% and 11 months. Iodine-125 has
improved the survival most demonstrably in poorer prog-
nostic classes so that a selection bias does not account for
the survival benefit [121,122].
Age has an important effect on survival with a median
survival of 109 weeks for patients aged 30-40 years, 96
weeks for 40-50 years, 77 weeks for 50-60 years and 76
weeks for 60 years and older [141]. Other factors affect-
ing outcome were KPS, superficial lesion, gross total
resection, reoperation, residual tumour volume, number
of seeds, seed activity, volume implanted and dose
[25,117,126,140,142,144].
A recurrence pattern analysis of patients treated in the
NCOG 6G-82-2 trial revealed that 77% were local
(within 2 cm from seed), 14% separate, 5% subependy-
mal and 5% systemic [136]. Others found 35% local,
65% marginal and 28% distant relapse [137] or 70%
local, 18% distant and 12% both [128].
Many different dose combinations of percutaneous
radiotherapy and iodine-125 brachytherapy have been
given in the primary therapy setting; 45Gy whole brain
radiotherapy and 100-280Gy (15-30cGy/h) brachyther-
apy boost [47], 59.4Gy (1.8Gy, 5×/week) or 40Gy (2Gy,
2×/day) and a high activity brachytherapy boost of 50Gy
[137], but most percutaneous and temporary seed dose
were 60Gy [139,141]. Sometimes radiotherapy was com-
bined with chemotherapy regimens [109,118,125,138] or
hyperthermia [145], or was given after seed implantation
[108].
For pre-irradiated, recurrent glioblastomas, seeds have
been implanted only without further percutaneous
radiotherapy. 100-500Gy of permanent seed dose have
been chosen [140,142] or 50-120Gy of temporary
[44,110,111].
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tomas have been performed, but brachytherapy does not
play a role in this setting nowadays. Standard therapy is
surgery and radiotherapy, plus concomitant and adjuvant
temozolomide [146]. In the recurrent setting, brachyther-
apy might be an option as interstitial irradiation can still
be employed in cases in which tolerance of the healthy
brain tissue has been reached because of previous external
irradiation [4]. Interstitial irradiation offers excellent pallia-
tion in a majority of patients with a significant amount of
long-term survivors for recurrent gliomas [147].
Brachytherapy of brain metastases
Besides primary brain tumours, interstitial brachytherapy
should be considered for brain metastases [148,149]. Some
accept a maximum diameter of 4 cm [150], others implant
3-6 cm metastases that are beyond the size limit of radio-
surgery [151]. The advantages of treating brain metastases
with brachytherapy are a minimally invasive procedure, a
minimal damage to normal brain tissue, no supplementary
risk by anaesthesia, no interference with other therapeutic
modalities, low stress for the patient, a short hospitalisa-
tion time (2-3 days) and low costs. The reasons why brain
metastases are ideal for interstitial irradiation are the fre-
quent spherical shape, the mostly relatively small size, the
normal brain parenchyma being displaced outside the
potential target volume and the minimally invasive growth
[152].
For metastases, local control rates of 73-95% have
been reported [153,154].
Median survival after implantation varies from 4 to 18
months, and 12- and 18-months survival rates from 33 to
72% and from 25 to 33% [104,115,145,149-151,153,
155-161].
Kreth et al. compared the median survival after
iodine-125 brachytherapy (60Gy, 10cGy/h, temporary),
percutaneous radiotherapy (40Gy, whole brain radio-
therapy) and a combination of both, for newly diagnosed
brain metastases, and observed median survival times of
12-15 months, 8 months and 17 months, respectively.
For recurrent metastases, survival times were around 6
months [104,150]. Results for singular brain metastases
are comparable with stereotactic radiosurgery [149].
For metastases, good prognostic factors are KPS ≥ 70,
solitary metastasis, no extracerebral metastases, long
time interval between primary diagnosis and diagnosis
of metastases [104,150,162].
A potential risk is growth of tumour cells by inocula-
tion along the catheter pathway, which was seen by
Ruge et al. in 6 out of 90 patients [154].
All in all, iodine-125 brachytherapy for metastases has
become more popular again in recent years due to its
radiobiological advantages and as it can be employed
even after extensive percutaneous pre-irradiation [120],
additionally biopsies are possible in the same session
[154,163].
Brachytherapy of pineal parenchymal tumours
Iodine-125 seeds (50-60Gy, 9-12cGy/h) have been used
for recurrent pineoblastomas [164]. A study of 18
patients (6-68 years) treated with 40-65Gy of permanent
(11) or temporary (7) implants for primary pineal
tumours or in a salvage situation has been published. 5
year overall actuarial survival rates of 100% for pineocy-
tomas and of 78% for high-grade tumours have been
reported. Complete remission rate was 72% and partial
remission rate 28%. Maarouf et al. concluded that iodine-
125 seeds are efficient and safe and an attractive alterna-
tive to microsurgery [165]. All in all, iodine-125 bra-
chytherapy treatment withal o wd o s er a t es e e m st ob e
an attractive, minimally invasive treatment option of
these rare tumour entities of the pineal region.
Various indications of brachytherapy
One group implanted petroclival meningiomas [26]. Treat-
ment of meningiomas of the skull base and other localisa-
tions with permanent iodine-125 implants results in a
complete response rate of 73-82% and a partial response
rate of 18-27%, without early, and with rare late complica-
tions [166-170]. The treatment of parasellar-clival and glo-
boid meningiomas with permanent implants showed a
slow reduction in volume with no mortality [171]. All
these results are only of historical interest as seeds do not
play a role in modern treatment of meningiomas.
Case reports present successful treatments of an exam-
ple of bilateral blindness secondary to a recurrent, preirra-
diated hemangiopericytoma of the pituitary fossa [172], or
of radiation-induced neoplasms [173]. Even a clival chor-
doma [174] and other skull base tumours [175,176] have
been treated with an implantation of seeds, as well as loca-
tions that are a challenge for high-precision percutaneous
radiotherapy [177,178]. A case of Rosai-Dorfman disease
of the central nervous system has been cured with bra-
chytherapy [179], as well as child optic pathway gliomas
[180]. Craniopharyngiomas have been implanted without
recurrences [181,182] and recurrent medulloblastomas
have been treated with iodine-125 brachytherapy [183].
Sometimes iodine-125 implants may have a favourable
long-lasting effect upon medically refractory seizures
[184].
Side effects and complications
The following side effects and complications have been
described in the literature: intracranial pressure and
tumour expansion due to necrosis, severe oedema, cere-
bral artery occlusion, intracranial haemorrhage and sub-
dural bleeding, headaches, nausea, vomiting, seizures,
increased neurological deficits, abscesses, aseptic and
septic meningitis, wound infections and dehiscence,
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fluid leakage, long-term steroid dependency, progressive
dementia, psychotic symptoms, facial pain, pulmonary
embolism and others [12,13,22,24,45-47,70,81,101,107,
110,114,134,137,138,155,185]. Two cases of devastating
strokes due to intracranial arterial occlusion have been
reported [43]. Tacke et al. found in 6 out of 13 children
with low-grade hypothalamic gliomas signs of vasculo-
pathy in magnetic resonance imaging, but only one
of them revealed symptoms of intermittent cerebral
ischemia [186].
No toxicity was reported in 92%, severe acute toxicity in
6%, life threatening in 1% and fatal in < 1% [25]. All in all,
t h eo p e r a t i v em o r b i d i t ys e e m st ob el o w( 1 . 2 - 2 1 . 7 % )
[67,79,95,107,150,155]. In patients with gliomas grade II, a
combination of surgery plus iodine-125 brachytherapy had
a morbidity of 27.8%, seed implantation alone of 6.4%
[102]. The perioperative mortality rate is max. 0.8-2.6%
[4,67,68].
Radiation toxicity (oedema) has been reported mostly
among patients treated with permanent implants
[101,104]. It occurs in 1.7-7.5% [68,95,96,101,104],
although for tumours greater than 3.5 cm in diameter, it
occurs in up to 18% of cases [101]. Late radiation necrosis
is a severe side effect which seems to occur in 40% of the
low-dose-rate implantations and is correlated with total
radiation dose, implanted activity and the velocity of
tumour shrinkage. It can be avoided by the usage of tem-
porary implants [85]. A detailed analysis of patients with
grade I and grade II gliomas undergoing low-activity
iodine-125 brachytherapy has revealed as risk factors for
radiogenic complications the volume of intratumoural
200Gy isodose and rapid tumour shrinkage of ≥ 50% of
the volume in six months. A 200Gy-isodose-volume of <
4.5ml leads to < 3% radiogenic complications with a steep
increase of the risk beyond this limit. For temporary
implants with a reference dose of 60Gy, the risk for com-
plications is < 3% if the treatment volume is ≤ 23 ml.
Further factors affecting the toxicity rate examined are the
overall treatment volume, the volume of the 60Gy isodose
outside the target volume, reimplantation, the reference
dose, the number of implanted seeds and a lobar tumour
location [96]. Other authors identified a target volume >
35ml and a permanent seed dose > 100Gy, or a temporary
> 50Gy, as risk factors of complications [105]. Evaluation
of a brain necrosis after permanent seed implantation
showed the necrotic area within the 100Gy isodose and
damage to the blood-brain barrier within the 50Gy isodose
[187]. A long term analysis of Kreth et al. revealed a risk
for radiogenic complications of about 9% for relatively
small grade II gliomas (diameter < 4 cm) and a steep
increase of complications (about 25%) for those harbour-
ing larger tumours (≥ 4 cm). The increase of radiogenic
complication rate beyond a critical threshold can be
explained by the tissue effects of brachytherapy, such as
the increase of capillary permeability in the vicinity of the
high-dose zone and the exponential increase of the
damaged capillary surface area product with the square of
the radius of the high-dose zone [16]. The risk of low-dose
rate brachytherapy of low-grade gliomas should not be
confused with the high frequency of complications (40-
50%) after high-dose rate treatment of malignant gliomas.
It remains difficult to elucidate, in which extent, additional
external beam radiation, the often relatively large size of
the treatment volume, and the applied high dose rate (in
the range of 35-50cGy/h), have contributed to these high
complication rates. Reoperation has been shown to be
required in 0-72% because of treatment induced space
occupying lesions, which occurred particularly after high
dose rate brachytherapy 3-183 weeks after implantation
[23,25,44-46,53,79,81,95,101,104,105,107,109-114,116-119-
,123,124,127,130,132,133,135-139,144,150,155,185,188,18-
9]. No correlation between implanted volume and need for
reoperation has been found [137]. However, there might
be a correlation for the combination of percutaneous
radiotherapy plus brachytherapy (64%), compared to per-
cutaneous radiotherapy only (15%) [137], others found
similar rates of around 30% for both groups [24]. Histolo-
gical findings (necrosis, tumour) at reoperation are not
prognostic factors [190].
Especially permanent seeds and periventricular loca-
tion, carry the risk of seed migration [133,191] but tem-
porary seeds also sometimes need repositioning [46,120].
Percutaneous catheter derived brachytherapy may be
associated with an increased incidence of extraneural
metastatic gliomas of the scalp, skull, cervical nodes, etc.
[192].
Quality of life
The quality of life in the majority of long-term survivors
appears to be quite satisfactory [23,44,45,193]. Comparing
permanent and temporary implants, the KPS remained
stable or improved in 85% and 58%. The neurological sta-
tus emended in 87% and 67% [115]. In another study the
neurological function has improved in 30%, has shown no
change in 43% and has declined in 27% [95]. The KPS
mostly improved in patients with astrocytomas II [104].
Summary and proposals for reduced side effects
In summary, to reduce the risk for side effects, temporary
implants, dose rates around 10cGy/h and activities <
20mCi should be preferred, high dose zones > 150Gy
should not be located within normal tissue and next to
vessels, and volumes > 4 cm should not be implanted. If
these guidelines are followed, then side effects are very
rare [16].
Conclusions
Iodine-125 brachytherapy might be indicated in highly
selected patients with recurrent brain tumours as a form
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with stable systemic disease and some other less com-
mon diagnoses, as it is a way to deliver an additional
dose of localized radiation to malignant brain tumours
while limiting radiation to the surrounding normal brain
tissue [13]. However, there is no strong randomized evi-
dence that would justify the change of guidelines for
any brain tumour entity. The side effects are rather rare.
During follow-up, attention has to be paid to some spe-
cial diagnostic features. In that case, iodine-125 seed
implantation in brain tumours may lead to good survival
rates and a decent quality of life.
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